Wide Ranks

KRYS

Krystal Biotech, Inc.

196.91

Top Statistics
Market Cap 5 B Forward PE 29.11 Revenue Growth 879.90 %
Current Ratio 7.97 Trailing PE 111.25 Earnings Growth -67.40 %
Profit Margins 21.68 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 73.50 Enterprise / Revenue 21.04 Price To Sales Trailing12 Months 23.45
Profitability
Profit Margins 21.68 % Operating Margins 41.67 %
Balance Sheet
Total Cash 588 M Total Cash Per Share 20.46 Total Debt 7 M
Total Debt To Equity 0.8440 Current Ratio 7.97 Book Value Per Share 30.80
All Measures
Short Ratio 1515.00 % Message Board Id finmb_534062888 Shares Short Prior Month 3 M
Return On Equity 0.0638 City Pittsburgh Uuid 7a984a25-100f-3abf-9545-b85fb5540d6c
Previous Close 196.52 First Trade Date Epoch Utc 1 B Book Value 30.80
Beta 0.8200 Total Debt 7 M Volume 139869
Price To Book 6.39 Fifty Two Week Low 100.78 Total Cash Per Share 20.46
Total Revenue 241 M Shares Short Previous Month Date 1 B Target Median Price 208.00
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins 41.67 %
Target Mean Price 207.78 Net Income To Common 52 M Short Percent Of Float 0.1651
Implied Shares Outstanding 28 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 232960 Average Volume10days 232960 Total Cash 588 M
Next Fiscal Year End 1 B Revenue Per Share 8.49 Held Percent Insiders 0.1230
Ebitda Margins 28.63 % Trailing PE 111.25 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 196.52 Target Low Price 195.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 179.98 Open 197.05
Free Cashflow 42 M State PA Dividend Yield 0.00 %
Return On Assets 0.0458 Time Zone Short Name EST Trailing Eps 1.77
Day Low 194.94 Address1 2100 Wharton Street Shares Outstanding 28 M
Price Hint 2 Target High Price 221.00 Website https://www.krystalbio.com
52 Week Change 0.8892 Average Volume 228109 Earnings Quarterly Growth -66.30 %
Forward Eps 5.85 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 765.80 % Is_sp_500 False Regular Market Day High 198.87
Profit Margins 21.68 % Debt To Equity 0.8440 Fifty Two Week High 219.34
Day High 198.87 Shares Short 3 M Regular Market Open 197.05
Industry Key biotechnology Earnings Growth -67.40 % Enterprise To Revenue 21.04
Revenue Growth 879.90 % Shares Percent Shares Out 0.1253 Operating Cashflow 63 M
Currency USD Time Zone Full Name America/New_York Market Cap 5 B
Is_nasdaq_100 False Zip 15203 Quote Type EQUITY
Industry Biotechnology Long Name Krystal Biotech, Inc. Regular Market Day Low 194.94
Held Percent Institutions 1.06 Current Price 196.91 Address2 Suite 701
Enterprise To Ebitda 73.50 Financial Currency USD Current Ratio 7.97
Gross Margins 92.55 % Industry Disp Biotechnology Number Of Analyst Opinions 9
Country United States Float Shares 22 M Two Hundred Day Average 176.66
Enterprise Value 5 B Price To Sales Trailing12 Months 23.45 Forward PE 29.11
Regular Market Volume 139869 Ebitda 69 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States.

It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.

Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.